PBSV on OTC

Pharma-Bio Serv, Inc.

Management consulting services company, listed on OTC (PBSV)1

In its 2026 annual report the company says: “Pharma-Bio Serv, Inc. is a Delaware corporation organized on January 14, 2004. The Company operates in Puerto Rico, the United States, Europe and Brazil under the name of Pharma-Bio Serv, and is engaged in providing technical compliance consulting services to the pharmaceutical, chemical, biotechnology, medical devices, cosmetic and food industries, and allied products companies.”4 It is headquartered in Dorado, Puerto Rico.1

Price unavailable

Last updated Oct 20, 2026.

Overview

Compare with rYojbaba Co., Ltd., RTB Digital, Inc. or DATZ WORLD HOLDINGS CORP., or pick any stock.

  • TickerPBSV on OTC1
  • IndustryServices-Management Consulting Services1
  • HeadquartersDorado, Puerto Rico1
  • Business addressIndustrial Zone Street 1, Lot 14, Dorado, Pr 006462
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Pharma-Bio Serv, Inc. (“Pharma-Bio” or the “Company”) is a Delaware corporation organized on January 14, 2004. The Company operates in Puerto Rico, the United States, Europe and Brazil under the name of Pharma-Bio Serv, and is engaged in providing technical compliance consulting services to the pharmaceutical, chemical, biotechnology, medical devices, cosmetic and food industries, and allied products companies. References to “we,” “us,” “our” and similar words in this Annual Report on Form 10-K refer to Pharma-Bio Serv, Inc. and its subsidiaries. Our website is www.pbsvinc.com. Information on our website or any other website is not part of this Annual Report on Form 10-K.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

32.3%Gross margin5
-7.1%Operating margin5
-1.1%Net margin5
-5.3%Revenue growth, 20255
-0.8%Return on equity5
-$221.5KFree cash flow5

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Regions

Puerto Rico Consulting brought in 52% of the revenue Pharma-Bio Serv, Inc. broke down this way in fiscal 2025.

  1. Puerto Rico Consulting$4.6M552%down 19% from 2024
  2. United States Consulting$2.6M529%down 17% from 2024
  3. Europe Consulting$1.7M519%up 202% from 2024
  4. Other$16.7K50%down 81% from 2024
Regions by year
Regions20242025
Puerto Rico Consulting$5.7M$4.6M
United States Consulting$3.2M$2.6M
Europe Consulting$571.2K$1.7M
Other$85.8K$16.7K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue63¢$6.1M
  • Selling, general and admin37¢$3.5M
  • Income tax0¢$6.2K

Out of $9.0M in revenue.5 The company lost money this year.

Financial statements

Revenue6789105$9.0M in 2025−54% since 2019
0$10.0M$20.0M$30.0M2019: $19.5M$19.5M20192020: $21.6M$21.6M2020+11%2021: $20.1M$20.1M2021−7%2022: $19.4M$19.4M2022−4%2023: $17.0M$17.0M2023−12%2024: $9.5M$9.5M2024−44%2025: $9.0M$9.0M2025−5%
Gross profit6789105$2.9M in 2025−53% since 2019
0$2.0M$4.0M$6.0M$8.0M2019: $6.2M$6.2M20192020: $6.7M$6.7M2020+8%2021: $5.4M$5.4M2021−20%2022: $4.9M$4.9M2022−9%2023: $5.1M$5.1M2023+4%2024: $2.5M$2.5M2024−50%2025: $2.9M$2.9M2025+16%
Operating income6789105-$637.7K in 2025
-$4.0M-$2.0M0$2.0M$4.0M2019: $1.7M$1.7M20192020: $2.2M$2.2M2020+31%2021: -$3.9M-$3.9M20212022: $1.2M$1.2M20222023: $1.1M$1.1M2023−5%2024: -$1.3M-$1.3M20242025: -$637.7K-$637.7K2025−50%
Net income6789105-$100.5K in 2025
-$4.0M-$2.0M0$2.0M$4.0M2019: $2.1M$2.1M20192020: $2.1M$2.1M2020−2%2021: -$2.1M-$2.1M20212022: $1.0M$1.0M20222023: $1.3M$1.3M2023+30%2024: -$777.6K-$777.6K20242025: -$100.5K-$100.5K2025−87%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-10-312024-10-31
REVENUES$9.0M$9.5M
COST OF SERVICES$6.1M$7.0M
GROSS PROFIT$2.9M$2.5M
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES$3.5M$3.8M
LOSS FROM OPERATIONS-$637.7K-$1.3M
OTHER INCOME, NET$543.4K$532.1K
LOSS BEFORE INCOME TAX-$94.3K-$755.4K
INCOME TAX EXPENSE$6.2K$22.2K
NET LOSS-$100.5K-$777.6K
BASIC AND DILUTED LOSS PER SHARE OF COMMON STOCK-$0.00-$0.03
SHARES OUTSTANDING - BASIC22.9M shares23.0M shares
SHARES OUTSTANDING - DILUTED23.0M shares23.0M shares

Compare Pharma-Bio Serv, Inc. with another company

Corporate structure

Pharma-Bio Serv, Inc. sits at the top of its group. 7 entities, 3 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

  • Pharma-Bio Serv, Inc. Dorado, Puerto Rico
    • Pharma Serv, Inc. Subsidiary · Puerto Rico, United States
    • Pharma-Bio Serv Brasil Servicos de Consultoria Ltda. Subsidiary · Brazil
    • Pharma-Bio Serv PR, Inc. Subsidiary · Puerto Rico, United States
    • Pharma-Bio Serv S.L. Subsidiary · Spain
    • Pharma-Bio Serv US, Inc. Subsidiary · Delaware, United States
    • Scienza Labs, Inc. Subsidiary · Puerto Rico, United States

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Pharma-Bio Serv, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$316.0K5 Oct 31, 2025$827.5K5 Oct 31, 2024−61.8%
Accumulated depreciation$199.9K5 Oct 31, 2025$658.2K5 Oct 31, 2024−69.6%
Property and equipment, net$116.1K5 Oct 31, 2025$169.3K5 Oct 31, 2024−31.4%
Operating-lease assets (leased space)$29.4K5 Oct 31, 2025$198.6K5 Oct 31, 2024−85.2%

Investments

ItemLatestA year beforeChange
Marketable securities, current$7.5M5 Oct 31, 2025$6.0M5 Oct 31, 2024+25.0%

Properties, in its own words

The Company previously performed its administrative operations in office facilities located in Dorado, Puerto Rico (the “Office Facilities”). The Office Facilities were under a lease agreement, which expired on December 31, 2025. As of January 1, 2026, we are a remote company and do not maintain physical offices, except for an office facility in Madrid, Spain, which is under a month-to-month lease with monthly payment of approximately $500.

For purposes of compliance with applicable requirements of the Securities Act and the Exchange Act, stockholder communications required to be sent to our principal executive offices may be directed to the Corporate Secretary, Pharma-Bio Serv, Inc., PO Box 1049, Dorado, Puerto Rico and info@pharmabioserv.com.

Item 2 of the 10-K filed Jan 29, 2026.4

Leadership

Who has led Pharma-Bio Serv, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Elizabeth Plaza2008–2012
  2. Altura Victor Sanchez2015–2023

Chair

  1. Elizabeth Plaza2006
  2. Kirk Wheeler Michel2021–now

President

  1. Elizabeth Plaza2008–2012
  2. Altura Victor Sanchez2015–2023

Chief financial officer

  1. Manuel O. Morera2007
  2. Pedro J. Lasanta2009–2023

Chief operating officer

  1. Mark A. Fazio2006
  2. Nelida Plaza Rodriguez2014
2010201520202025
Board members and other officers (6)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Pharma Serv, Inc. Puerto Rico3
  • Pharma-Bio Serv Brasil Servicos de Consultoria Ltda. Brazil3
  • Pharma-Bio Serv PR, Inc. Puerto Rico3
  • Pharma-Bio Serv S.L. Spain3
  • Pharma-Bio Serv US, Inc. Delaware3
  • Scienza Labs, Inc. Puerto Rico3

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • LAWRENCE CONSULTING GROUP INCSep 24, 2004 to Feb 28, 20062

Timeline

  1. Sep 14, 20268-K Results of operations27
  2. Jun 15, 20268-K Results of operations28
  3. May 15, 20268-K Shareholder vote29
  4. Mar 17, 20268-K Results of operations30
  5. Jan 29, 20268-K Results of operations31
  6. Sep 15, 20258-K Results of operations32
  7. Jun 16, 20258-K Results of operations33
  8. May 16, 20258-K Shareholder vote34
  9. Mar 17, 20258-K Results of operations35
  10. Jan 29, 20258-K Other events36
  11. Jan 29, 20258-K Results of operations37
  12. Sep 16, 20248-K Results of operations38
  13. Jan 12, 2015New chief executive Altura Victor Sanchez becomes CEO14
  14. Jul 11, 2008New chief executive Elizabeth Plaza becomes CEO15

Calendar

Coming up

  1. Around Dec 14, 2026Next results, estimated About a quarter after its last report. The company hasn't announced the date.

When it reported results

  1. Sep 14, 2026Reported quarterly or annual results27
  2. Jun 15, 2026Reported quarterly or annual results28
  3. Mar 17, 2026Reported quarterly or annual results30
  4. Jan 29, 2026Reported quarterly or annual results31
  5. Sep 15, 2025Reported quarterly or annual results32
  6. Jun 16, 2025Reported quarterly or annual results33
  7. Mar 17, 2025Reported quarterly or annual results35
  8. Jan 29, 2025Reported quarterly or annual results37

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

101 filings to the SEC since October 2021: 10 annual reports, 15 quarterly reports, 31 major events, 35 insider forms, 10 other. The latest 20:

  1. Sep 14, 20268-K EDGAR
  2. Sep 14, 202610-Q EDGAR
  3. Jul 22, 20264 PRIMARY DOCUMENT EDGAR
  4. Jun 15, 20268-K EDGAR
  5. Jun 15, 202610-Q EDGAR
  6. May 15, 20268-K EDGAR
  7. Apr 16, 2026ARS EDGAR
  8. Apr 16, 2026DEF 14A EDGAR
  9. Mar 17, 20268-K EDGAR
  10. Mar 17, 202610-Q EDGAR
  11. Feb 27, 202610-K/A EDGAR
  12. Jan 29, 20268-K EDGAR
  13. Jan 29, 202610-K EDGAR
  14. Jan 14, 20264 EDGAR
  15. Jan 14, 20264 EDGAR
  16. Jan 14, 20264 EDGAR
  17. Jan 14, 20264 EDGAR
  18. Sep 15, 20258-K EDGAR
  19. Sep 15, 202510-Q EDGAR
  20. Jun 16, 20258-K EDGAR

The 101 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Victor Sanchez55$231.0K$245.9K39
2025Pedro Lasanta66$175.0K$175.6K39
2024President and Chief Executive Officer$231.0K$245.9K39
2024Chief Financial OfficerVice President-Finance and Administration and Secretary$175.0K$182.0K39

SEC filer profile

How Pharma-Bio Serv, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARPharma-Bio Serv, Inc.1
  • CIK0001304161
  • Employer ID (EIN)20-06535704
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company4
  • Incorporated inDelaware4
  • Fiscal year endsOctober 311
  • Industry code (SIC)8742 Services-Management Consulting Services1
  • SEC reviewing officeOffice of Trade & Services, Division of Corporation Finance1
  • Business addressIndustrial Zone Street 1, Lot 14, Dorado, PR 006461
  • Phone787-278-27091
  • Shares outstanding22,901,692 as of Sep 10, 202613
  • Public float$6.1M as of Apr 30, 20254
  • AuditorCROWE PR PSC, Guaynabo, Puerto Rico PCAOB ID 871; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceSep 24, 20041
  • Filings527 in all: 4 (150), 8-K (134), 10-Q (54), DEF 14A (19), 10-K (18), 10-K/A (16), 10QSB (14), SC 13D/A (14)1
    All 34 form types

    3 (13), ARS (10), UPLOAD (10), SC 13D (8), 10QSB/A (7), SB-2/A (6), NT 10-K (5), POS AM (5), 4/A (4), 424B3 (4), 8-K/A (4), CORRESP (4), EFFECT (4), 10KSB (3), NO ACT (3), NT 10-Q (3), 10KSB/A (2), PRE 14A (2), REGDEX (2), S-8 (2), SC 13G (2), 10SB12G (1), DEF 14C (1), DEFR14C (1), SB-2 (1), SC 13G/A (1)

  • Latest filingsAnnual report (10-K) Jan 29, 2026
    Quarterly report (10-Q) Sep 14, 2026
    Proxy statement (DEF 14A) Apr 16, 2026
    Latest 8-K (8-K) Sep 14, 2026

Risk factors and legal proceedings

The risks Pharma-Bio Serv, Inc. names in Item 1A of its 10-K filed Jan 29, 2026: 26 risks under these headings, as written.4

  • Operational Risks
  • Because our business is concentrated in the life science and medical devices industries in Puerto Rico, the United States and Europe, any changes in those industries or in those markets could impair our ability to generate revenue and realize a profit.
  • Puerto Rico’s economy, including its governmental budgetary constraints, declining population growth, and the impact of hurricanes or any other natural disasters, including earthquakes, may affect the willingness of businesses to commence or expand operations in Puerto Rico, or may also consider closing operations located in Puerto Rico.
  • Because our business is dependent upon a small number of clients, the loss of a major client could impair our ability to operate profitably.
  • The collectability of our accounts receivable may be subject to our customers’ operations and funding sources.
  • Customer procurement and sourcing practices intended to reduce costs could have an adverse effect on our margins and profitability.
  • We may be unable to pass on increased labor costs to our clients.
  • Consolidation in the pharmaceutical industry may have a harmful effect on our business.
  • We may be held liable for the actions of our employees or contractors when on assignment.
  • To the extent that we perform services pursuant to fixed-price or incentive-based contracts, our cost of services may exceed our revenue on the contract.
  • Because most of our contracts may be terminated on little or no advance notice, our failure to maintain or generate new business could impair our ability to operate profitably.
  • Because we are dependent upon our management and technical personnel, our ability to develop our business may be impaired if we are not able to engage skilled personnel.
The other 15 risks
  • Our cash could be adversely affected if the financial institutions in which we hold our cash fail.
  • We may be harmed if we do not penetrate markets and expand our current business operations.
  • Disruptions in our information technology systems could adversely affect our business and the results of operations. If these systems fail or become unavailable for any period of time this could limit our ability to effectively monitor and control our operations and adversely affect our operations. Additionally, a breach or an alleged breach of our information technology systems could subject us to liability or reputational damage.
  • Regulatory Risks
  • Because the pharmaceutical industry is subject to government regulations, changes in government regulations relating to this industry may affect the need for our services.
  • The prices of prescription pharmaceuticals in the U.S. and foreign jurisdictions are subject to considerable legislative and executive actions and could impact the prices of our customers products.
  • Changes in tax laws in the United States, Puerto Rico or in other jurisdictions where we do business may adversely impact the willingness of our customers to continue or to expand their operations where we do business and may also impact our tax business model.
  • Changes to trade regulation, quotas, duties or tariffs, caused by the changing U.S. and geopolitical environments or otherwise, may materially adversely affect customer demand for our services.
  • If we are unable to renegotiate the term of the tax grant issued by the Puerto Rico Industrial Development Company (“PRIDCO”) we may incur increased tax payments, which could have a material adverse effect on our business, financial condition, results of operations, and cash flow.
  • Intellectual Property Risks
  • Since our business is dependent upon the development and enhancement of patented pharmaceutical products or processes by our clients, the failure of our clients to obtain and maintain patents could impair our ability to operate profitably.
  • If we are unable to protect our clients’ intellectual property, our ability to generate business will be impaired.
  • We may be subject to liability if our services or solutions for our clients infringe upon the intellectual property rights of others.
  • Common Stock Risks
  • Because there is a limited market in our common stock, stockholders may have difficulty in selling our common stock and our common stock may be subject to significant price swings.
  • Our revenues, operating results and profitability will vary from quarter to quarter, which may result in increased volatility of our stock price.
  • We cannot guarantee that our Stock Repurchase Program will be fully implemented or that it will enhance long-term stockholder value.
  • The issuance of securities, whether in connection with an acquisition or otherwise, may result in significant dilution to our stockholders.

Legal proceedings

From time to time, we may be a party to legal proceedings incidental to our business. Currently, there are no proceedings threatened or pending against us, which, if determined adversely to us, would have a material effect on our financial position or results of operations and cash flows. However, the Company is a complainant in one legal proceeding as described below.

On March 15, 2023, the Company’s subsidiaries Pharma-Bio Serv PR, Inc., Pharma Serv, Inc. and Scienza Labs, Inc., filed a breach of contract and money collection complaint against Romark Global Pharma, LLC, Romark Properties, LLC, Romark Biosciences, LLC and Romark Holdings, LLC (collectively, “Romark”), before the Commonwealth of Puerto Rico Court of First Instance, San Juan Superior Section. On November 13, 2023, a judgment was entered by the Court ordering Romark to pay jointly to the Company’s subsidiaries $6,717,431.69, which includes the principal amount of $5,246,782, plus interest up to the date of the judgment. The Company’s subsidiaries are pursuing assets and monies from Romark to collect the judgment. To this date, however, we have been unable to identify assets of Romark against which to collect. Also, multiple other creditors of Romark have filed claims against it. Aside from legal fees and the costs of identifying assets, and costs of collection efforts, no further losses are expected. The Company’s subsidiaries will continue the collection efforts with Romark. However, we cannot guarantee a successful outcome in collecting the funds owed to the Company’s subsidiaries.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
    SEC EDGAROther events
  37. 37
  38. 38
  39. 39